 |
|
|
| |
CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50 FC, AND HIV-1 SUBTYPE IN BRIGHTE
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Poster pdf attached
M Gartland,1 P Ackerman,2 F Mannino,3 L Garside,4 A Clark,5 A Pierce,1 M Krystal,2 C Llamoso,2 M Lataillade2
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Branford, CT, USA; 3GlaxoSmithKline, Collegeville, PA, USA; 4GlaxoSmithKline, London, UK; 5ViiV Healthcare, London, UK
|
| |
|
|
|
|
|
